ClinicalTrials.gg

Program

notiretatug rezetecan

Also written as “SHR-A2102”, “SHR-A2102 for Injection” and “SHR-A2102 ; Adebrelimab injection”.

In Jiangsu HengRui Medicine’s pipeline, Nectin-4 ADC. Its studies are mostly in Urinary Bladder Neoplasms · Carcinoma, Transitional Cell · Squamous Cell Carcinoma of Head and Neck · Uterine Cervical Neoplasms · Carcinoma, Non-Small-Cell Lung, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Dec 12, 202414 company-led studies, 14 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine1414 open or runningphase 3since Dec 12, 2024Jan 18, 2023Dec 2026phase 2 · NCT06915142
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-A2102, phase 3, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 18, 2023First studies: 2 phase 1 studiesFirst studyNCT05701709, NCT05735275
  2. Apr 26, 2024Phase 2 study in Advanced Solid TumorsNCT06417554 · 80 planned · China
  3. Jun 6, 2024Phase 2 study in Esophageal NeoplasmsNCT06474468 · 148 planned · China
  4. Oct 10, 20242 phase 2 studiesNCT06639347, NCT06654440
  5. Dec 12, 2024Phase 3 study in Advanced Urothelial CarcinomaNCT06738251 · 402 planned · China
  6. Mar 11, 2025Phase 3 study in Muscular Invasive Bladder Cancer (MIBC)NCT06879145 · 740 planned · China
  7. Mar 20, 2025Phase 2 study in Advanced Solid TumorsNCT06895928 · 400 planned · China
  8. Apr 1, 2025Phase 2 study in Advanced Malignant TumourNCT06915142 · 300 planned · China
  9. Jul 1, 2025Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07059221 · 210 planned · China
  10. Sep 9, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07175220 · 200 planned · China
  11. Jan 30, 2026Phase 3 study in Carcinoma, Transitional CellNCT07393542 · 453 planned · China
  12. Feb 11, 2026Phase 3 study in Uterine Cervical NeoplasmsNCT07418749 · 398 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Advanced Malignant TumourNCT06915142
  2. Mar 2027Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07059221
  3. May 31, 2027Primary completion: phase 2 study in Advanced Urothelial CarcinomaNCT06639347
  4. Dec 2027Primary completion: phase 3 study in Uterine Cervical NeoplasmsNCT07418749

TargetBeta

“Nectin-4 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of notiretatug, an immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) nectin-4 (PVRL4) conjugated, via a cleavable linker, to rezetecan, a derivative of the topoisomerase-1 inhibitor exatecan, with potential a…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of notiretatug, an immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) nectin-4 (PVRL4) ”NCIt, by rule

Other programs on NECTIN4

ProgramCompanyFurthest phaseStudies
enfortumab vedotinruleAstellas Pharmaphase 420
bulumtatug fuvedotinruleMabwell (Shanghai) Biosciencephase 313
Sutantatug EnvedotinruleCSPC Pharmaceutical Groupphase 36
zelenectide pevedotinrulebicycletx-limitedphase 25
Anti-nectin-4 Antibody-drug Conjugate MK-3120ruleMerckphase 25
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-nectin-4 Antibody-drug Conjugate IPH4502ruleinnate-pharmaphase 11
Anti-nectin-4/CD28 Bispecific Antibody RNDO-564rulerondo-therapeuticsphase 11
CT-202rulecontext-therapeutics-incphase 11

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07418749Uterine Cervical Neoplasms · China3RecruitingDec 2027398
NCT07393542Carcinoma, Transitional Cell · China3RecruitingJan 31, 2028453
NCT07175220Carcinoma, Non-Small-Cell Lung · China2RecruitingOct 2028200
NCT07059221Squamous Cell Carcinoma of Head and Neck · China2RecruitingMar 2027210
NCT06915142Advanced Malignant Tumour · China2RecruitingDec 2026300
NCT06895928Advanced Solid Tumors · China2RecruitingDec 2028400
NCT06879145Muscular Invasive Bladder Cancer (MIBC) · China3RecruitingDec 2031740
NCT06738251Advanced Urothelial Carcinoma · China3RecruitingJul 2026402
NCT06654440Advanced Gynecological Malignancy · China2RecruitingAug 31, 2025100
NCT06639347Advanced Urothelial Carcinoma · China2RecruitingMay 31, 202790
NCT06474468Esophageal Neoplasms · China2RecruitingOct 2026148
NCT06417554Advanced Solid Tumors · China2RecruitingDec 31, 203180
NCT05735275Advanced Or Metastatic Solid Tumor Malignancies · China1RecruitingAug 31, 2025252
NCT05701709Advanced Solid Tumors · China1RecruitingAug 31, 2025395

How it is read

Names in the registry

  • “SHR-A2102”, 7 entries
  • “SHR-A2102 for Injection”, 2 entries
  • “SHR-A2102 ; Adebrelimab injection”, 1 entry
  • “SHR-A2102 + Disitamab Vedotin For Injection”, 1 entry
  • “SHR-A2102 and Adebrelimab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.